Risk Factors for Blood Product Usage Following Sibling Allogeneic Haemopoietic Stem Cell Transplantation (allo-HCT).
Nicola Hurst, Charles G Mullighan, Sue L Heatley, Kathryn Robinson, Silke Danner, Uwe Hahn, Jeff Szer, Peter Shuttleworth, Rosie Hoyt, Anthony P Schwarer, Jenny Muirhead, Kenneth Bradstock, Lisa Miller, Peter G Bardy
Blood | American Society of Hematology | Published : 2007
Abstract Red cell and platelet transfusion requirements have been reported to be lower following reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC allo-HCT) when compared to myeloablative (MA) allo-HCT. However, previous studies examined RIC regimens with lower haemopoietic toxicity than many of the regimens in use today. We investigated risk factors for red cell and platelet transfusion in patients enrolled prospectively in an Australian study investigating the non-HLA immunogenetics of sibling allo-HCT. The transfusion requirements in the first year post transplant were reviewed for 122 patients transplanted between 2002 and 2006 in three..View full abstract